COMPANY OVERVIEW. October 12, 2017
|
|
- Amanda Washington
- 6 years ago
- Views:
Transcription
1 COMPANY OVERVIEW October 12, 2017
2 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the development and commercialization of new products; our ability to secure and maintain necessary regulatory approvals for our existing products and new products under development. Our estimates and forward-looking statements are based on our management s current assumptions and expectations of future events and trends, which affect or may affect our business, strategy, operations or financial performance. These statements are not guarantees of future performance and involve a number of risks and uncertainties, many of which are beyond our control. Our actual results may differ materially from those expressed or implied by such forward-looking statements. Some of the factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements can be found under the captions Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, as well as in the other reports we file with the Securities and Exchange Commission. In addition, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by law, we undertake no obligation to update or review any estimate and forward-looking statement because of new information, future events or other factors. Non-GAAP Financial Measures This presentation references certain non-gaap financial measures, including, without limitation, non-gaap sales and non-gaap operating margin. These non-gaap measures have not been calculated in accordance with GAAP and should not be considered an alternative for measures prepared in accordance with GAAP. The presentation of non-gaap information is not meant to be considered superior to, in isolation from or as a substitute for results prepared in accordance with GAAP. We believe these non-gaap financial measures enhance investors overall understanding of our current financial performance and our prospects for the future. A reconciliation of the non-gaap financial measures corresponding to the GAAP financial measures is provided on slide 25. 2
3 TANDEM DIABETES CARE Technology for Simply Better Life Only touchscreen interface, remote updatable, intuitive platform with contemporary style and compact size Nearly 56,000 pumps shipped in the past 4 years, representing approximately 10% market share 1 5 new insulin pumps launched since the introduction of t:slim in 2012 #1 rated customer support by pump users since % of HCPs surveyed believe providing great pump customer support is the most important company attribute 3 Robust, near-term product pipeline Key sales projections and cash metrics 4 Q non-gaap sales (est.): $23M - $24M, Q non-gaap sales (projected): $33M - $38M Cash balance at September 30, 2017: $22.5M Goal to reach profitability in 2019 Increasing sales driven by new products, pump renewals and international commercialization Improving gross profits through lower per unit cost of manufacturing and reduced warranty expense Leveraging existing operating infrastructure 1) Based on 550,000 pumpers in the U.S. and cumulative pump shipments through 9/30/17; 2) dq&a USA Connections Surveys ; 3) Tandem HCP Research Report, Summer 2015; 4) Non-GAAP sales are determined in accordance with GAAP, adjusted for the impact of the Technology Upgrade Program. See the information under the heading GAAP to Non-GAAP Financial Measures" on slide 2. Refer to GAAP to non-gaap reconciliation on slide 25. Management s current assumptions and estimates are based on historical patterns, excluding FY See slide 2 for information regarding forward-looking statements and additional risks and uncertainties that could cause actual outcomes or results to differ materially. 3
4 DIABETES OVERVIEW Cause Onset Type 1 Type 2 Autoimmune Body does not create insulin hormone Sudden Typically before age 40 Lifestyle Related Insulin resistance where cells do not use insulin properly Progressive Typically appears late in life Prevention None Diet and exercise Therapy Insulin Oral medication, insulin U.S. Prevalence million Apx. 20 million, of which 1.7 million use daily rapid acting insulin Number Using Pump Therapy 1 425, ,000 1) Close Concerns, Insulin Pump Market Overview, January
5 THE HUMAN TOLL OF DIABETES Mental Fear Frustration Embarrassment Anxiety Stress Physical Damage to tissue and organs Coma or even death Seizures Exhaustion Vomiting 5
6 INSULIN REPLACEMENT THERAPY Multiple Daily Injection MDI Continuous Subcutaneous Insulin Infusion CSII 6
7 PUMP THERAPY IS OPTIMAL Basel and Bolus Insulin Release Like The Pancreas Blood Glucose Levels 7
8 T:SLIM X2 THE PUMP THAT GETS UPDATED, NOT OUTDATED Our Flagship Product Only remote updatable insulin pump; intuitive touchscreen interface with contemporary style and compact size Ease of use provides clinical benefits 1,2 Only available pump with Dexcom G5 CGM integration The first step in our mobile health innovation The only Bluetooth enabled pump Key to patient data management Proven ability to attract people using MDI 1) Schaeffer N, McCoy S, Dokken B, Stal M, Shearin E, Chen P, Navarrete J. Touchscreen sensor-augmented insulin pump (SAP) demonstrates less exposure to hypoglycemia and increased time in range compared to non-touchscreen SAPs [Session #EP08]. Paris, France: 10th Annual Advanced Technologies and Treatments for Diabetes Conference; ) Manning M, Noar A, Marin G, Dokken B. Self-reported hypoglycemia reduction in Tandem pump use compared to previous methods of diabetes therapy 8 [session #EP08]. Paris, France: 10th Annual Advanced Technologies and Treatments for Diabetes Conference;
9 DEXCOM TECHNOLOGY BENEFITS OUR PATIENTS ECOSYSTEM Dexcom G5 Adult MARD 9% Medtronic Guardian 10.6% (Based on 2 calibrations/day) Finger Sticks/Day Calibration 2 calibrations/day required 4 calibrations/day recommended 2 calibrations/day required Glucose Data Sharing SHARE feature allows up to five followers to monitor a user s glucose None Source: Company websites and product user guides. 9
10 TANDEM DEVICE UPDATER Simplifying Life Through Technology Only updatable pump system available Significant opportunity to drive product adoption by offering new software updates G5 integration offered to 12,000+ t:slim X2 customers within days following approval One-third of t:slim X2 customers updated their software within 30 days following approval 85% of customers who updated indicated they were satisfied or extremely satisfied with the update process 10 10
11 THE GOAL OF AUTOMATED INSULIN DELIVERY NORMAL GLUCOSE CONTROL 11
12 PLGS: PREVENTING HYPOGLYCEMIA Further Improving Patient Lives t:slim X2 with Predictive Low-Glucose Suspend Reduces basal insulin to help minimize the frequency and duration of hypoglycemic events Algorithm utilizes Dexcom s G5 CGM data Designed for software to be offered to current t:slim X2 customers Milestones completed: Feasibility study successfully completed in August 2016 Pivotal Study IDE approved by the FDA in May 2017 Enrollment for pivotal study commenced in August 2017 Next steps: Completion of pivotal study anticipated by YE 2017 Launch goal: summer 2018, subject to FDA approval Note: The graphics presented on this page are for illustrative purposes only, and do not reflect individual results 12 12
13 HYBRID CLOSED LOOP (HCL): BETTER LIFE, LESS BURDEN Leap-frogging the Competition t:slim X2 with Hybrid Closed Loop Increase or decrease basal insulin to minimize hyper/hypoglycemia and improve time-in-range Deliver automated correction boluses Brings together leading technology - t:slim X2 Pump, Dexcom s G6 CGM sensor and TypeZero algorithms Data collected in NIH-funded International Diabetes Closed Loop (IDCL) Trial to be used in Tandem PMA submission Launch goal: 1H 2019, subject to FDA approval Note: The graphics presented on this page are for illustrative purposes only, and do not reflect individual results 13 13
14 T:SPORT EVEN GREATER DISCRETION & FLEXIBILITY Refining product requirements through market research 50% of t:slim s size Uses a short infusion set Controlled via a separate device or mobile app Gives durable pumpers a more discreet option Preserves current reimbursement model Active development Resource prioritization to automated insulin delivery products Controller Pump 14 14
15 BLUETOOTH ENABLES OUR MOBILE HEALTH STRATEGY 1. t:connect (pumping, BG and CGM data) #1 rated consumer software by pump users since % of Tandem customers have a t:connect account 2 Upload 3 times per month, on average 2. t:connect HCP Streamlines t:connect use for multiple patients and office efficiency 3. Tandem mobile application (in development) Wirelessly upload data to t:connect Integration of data from 3 rd party sources Receive notification of pump alerts and alarms Designed to support future pump-control capabilities 1. dq&a USA Patient Connections Surveys, Data on file. Tandem Diabetes Care, Inc
16 OUR PATHWAY TO PROFITABILITY Differentiated Current Portfolio Innovative Pipeline New, Incremental Revenue Opportunities Improving Gross Profits and Cash Flow Tandem Device Updater only updatable pump Clinical benefits Only available pump with Dexcom G5 integration Superior form factor enabled by differentiated technology Only pump with a touchscreen t:slim X2 with G5 & PLGS t:slim X2 with G6 & HCL Mobile application t:sport Capture infusion set sales through our t:lock Connector Growing pump renewals opportunity International markets Reduce component costs Reduce warranty costs Manage scale of operating expenses 16 16
17 PUMPS ARE THE KEY DRIVER Reimbursement Frequency Pump Cartridge Infusion Set Once every 4 years Once every 3 days (120/year) Once every 3 days (120/year) Payor Reimbursement $4,000 - $5,000 $ $3.00 $ $10.00 Network of distributors used for 70% - 75% of sales Distributors pricing adjusted for a logistics margin Pumps represent greatest percent of sales due to significant ASP differences Not a traditional razor/razorblade model due to reoccurring pump reimbursement cycle Infusion sets make up 60% - 70% of a direct customer s annual supplies revenue (apx. $1,200 - $1,600) Infusion set revenue was typically lost prior to 2017 due to distributors purchasing dynamics 17 17
18 INSULIN PUMP BUSINESS MODEL Highly seasonal business Sales are typically back-end loaded (Q1 lowest percent of sales, Q4 highest percent of sales) Highly influenced by timing of when people typically meet their insurance deductibles Customer Order Payor Contract? DTC sales model (commercial payors and patient coinsurance) Billed using existing HCPC codes with longstanding defined allowable rates Utilize direct contracts with commercial payors or distributor arrangements Distributors earn a logistical (not selling) margin Volume based discounting for infusion set sales Process w/ Payor Process w/ Distributor Single Case Agreement Allowed? Negotiate Single Case Agreement w/ Payor 18
19 MEANINGFUL PROGRESS TOWARD PROFITABILITY Actual ($ in 000 s) Total Product Sales $29.0 $ 49.7 $ 72.9 $88.5 Pump Shipments 6,472 10,822 15,483 16,938 Gross Profit $6.2 $15.3 $26.6 $28.2 Operating expense $55.6 $90.9 $95.6 $101.6 Operating Loss % -170% -152% -95% -83% 1 Compound annual sales growth of more than 30% from 2013 to non-gaap sales estimate: $95M - $100M 1 Improvement of gross profits driven by higher pump gross margins and steady increases of pump supplies volume Operating expenses have grown at a much slower rate than sales and gross profits Leveraging multiple products, the easy to train/easy to use aspects of our products and common hardware platform of our pipeline 1) GAAP; 2016 and 2017 Non-GAAP. Non-GAAP sales are determined in accordance with GAAP, adjusted for the impact of the Technology Upgrade Program. See the information under the heading GAAP to Non-GAAP Financial Measures" on slide 2. Refer to GAAP to non-gaap reconciliation on slide 25. Management s current assumptions and estimates are based on historical patterns, excluding FY See slide 2 for information regarding forward-looking statements and additional risks and uncertainties that could cause actual outcomes or results to differ materially 19
20 THE IMPACT OF SEASONALITY Percent of Yearly Shipments 45% 40% 35% 30% 25% 20% 15% 10% 5% 2016 seasonality masked by: 1H strength from t:slim G4 launch 2H competitive headwinds 0% 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 E 4Q17 E Sales $8M $10M $14M $18M $12M $16M $16M $29M $20M $23M $21M $25M $18M $21M $23M- $24M Gross Margin 11% 34% 33% 37% 23% 31% 35% 46% 35% 36% 26% 31% 35% 38% 1 1 $33M - $38M 1) Q is preliminary and not yet complete. Q is based on management s current assumptions and estimates based on historical patterns where 35% - 38% of our annual sales have typically been in the fourth quarter, excluding FY See slide 2 for information regarding forward-looking statements and additional risks and uncertainties that could cause actual outcomes or results to differ materially. Note: GAAP; 2016 and 2017 Non-GAAP. Non-GAAP sales and gross margin are determined in accordance with GAAP, adjusted for the impact of the Technology Upgrade Program. See the information under the heading GAAP to Non-GAAP Financial Measures" on slide 2. Refer to GAAP to non-gaap reconciliation on slide
21 DRIVING TOWARD PROFITABILITY AT 15% MARKET SHARE 1 Launched t:flex (May) & t:slim G4 (Sept) Launched t:slim X2 (Oct) 9% Launched t:slim X2 with G5 (Aug) 11% Competitive opportunity Renewals 15% 6% t:slim X2 PLGS t:slim X2 HCL 3% International 1% E Goal 2 1) Based on 550,000 pumpers in the U.S. and cumulative pump shipments through 9/30/17 2) Based on management s current assumptions and estimates. See slide 2 for information regarding forward-looking statements and additional risks and uncertainties that could cause actual outcomes or results to differ materially. 21
22 MEANINGFUL GROSS MARGIN PROGRESS E 55% Increased Production Volumes A& Manufacturing B Process Improvements 32% Increased Production Volumes Reduction in Component Costs Improved Warranty Costs 21% Goal Pumps: largest percent of sales, greatest impact on gross margin Expected 20% reduction in pump component cost 2016 to 2017 Reduction in warranty expense from 12% of sales in 2016 to 7% in 1H Positive supplies gross margin Breakeven was reached Q3 2016; increasingly positive margin each subsequent quarter 1) 2016 is Non-GAAP. Non-GAAP gross margin is determined in accordance with GAAP, adjusted for the impact of the Technology Upgrade Program. See the information under the heading "Use of Non-GAAP Financial Measures" on slide 2. Refer to GAAP to non-gaap reconciliation on slide 25. 2) Based on management s current assumptions and estimates. See slide 2 for information regarding forward-looking statements and additional risks and uncertainties that could cause actual outcomes or results to differ materially. 22
23 CATALYSTS TO 2019 PROFITABILITY GOAL Q first full quarter offering t:slim X2 with G5 Only available Dexcom G5 sensor integrated pump Validation of the Tandem Device Updater Animas exiting the market 90,000 customers worldwide Multiple clinical trial milestones for two automated insulin delivery products Renewal opportunity 1 10,500 pumps in ,500 pumps in 2019 Infusion set strategy to capture 100% of sales on track for achievement by year end 2017 Gross margin improvements driven by lower pump costs and warranty costs; greater impact with increased pump volumes 1) Assumes 4 year reimbursement cycle for total pump shipments in 2014 and
24 TANDEM DIABETES CARE Technology for Simply Better Life Only touchscreen interface, remote updatable, intuitive platform with contemporary style and compact size Nearly 56,000 pumps shipped in the past 4 years, representing approximately 10% market share 1 5 new insulin pumps launched since the introduction of t:slim in 2012 #1 rated customer support by pump users since % of HCPs surveyed believe providing great pump customer support is the most important company attribute 3 Robust, near-term product pipeline Key sales and cash metrics 4 Q non-gaap sales (est.): $23M - $24M, Q non-gaap sales (projected): $33M - $38M Cash balance at September 30, 2017: $22.5M Goal to reach profitability in 2019 Increasing sales driven by new products, pump renewals and international commercialization Improving gross profits through lower per unit cost of manufacturing and reduced warranty expense Leveraging existing operating infrastructure 1) Based on 550,000 pumpers in the U.S. and cumulative pump shipments through 9/30/17; 2) dq&a USA Connections Surveys ; 3) Tandem HCP Research Report, Summer 2015; 4) Non-GAAP sales are determined in accordance with GAAP, adjusted for the impact of the Technology Upgrade Program. See the information under the heading GAAP to Non-GAAP Financial Measures" on slide 2. Refer to GAAP to non-gaap reconciliation on slide 25. Management s current assumptions and estimates are based on historical patterns, excluding FY See slide 2 for information regarding forward-looking statements and additional risks and uncertainties that could cause actual outcomes or results to differ materially. 24
25 GAAP TO NON-GAAP RECONCILIATION 1 Sales (in millions) Q1 Q2 Q3 Q4 Q1 Q2 GAAP $20.1 $23.0 $12.3 $28.9 $19.0 $21.3 Non-GAAP - - $20.7 $24.8 $17.5 $21.3 Gross Profit GAAP $6.9 $8.2 ($1.6) $10.1 $6.8 $8.0 Non-GAAP - - $5.4 $7.7 $6.0 $8.1 Gross Margin GAAP 35% 36% (13%) 35% 36% 38% Non-GAAP % 31% 35% 38% 1) A Technology Upgrade Program was launched in Q Sales and cost of sales for eligible t:slim and t:slim G4 shipments were subject to deferral beginning 7/1/16. The amount deferred varied based on a number of factors, including the model of pump involved and the timing of the initial sales relative to the availability of certain future products. In general, the deferrals had the effect of initially decreasing our GAAP sales even when the number of our pump shipments increased. We discontinued new sales of the t:slim and sales of the t:slim G4 significantly decreased following the launch of the t:slim X2 in Q4 2016, resulting in a significant decrease in the amount of sales and cost of sales related to new product shipments that were deferred under the program. The deferred amount of sales and cost of sales are recognized at the earlier of when the obligations under the Technology Upgrade Program are satisfied or when the program expires. If a customer elected to participate in the Technology Upgrade Program, we recognized upgrade fees received, if any, and the associated costs at the time of fulfilling the obligation. We expect to recognize the majority of the remaining deferred sales and cost of sales in the quarter ended September 30, 2017 when the program expires. 25
26 Questions? Contact Investor Relations T: x7005 E:
COMPANY OVERVIEW. April 26, 2018
COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationInstitutional Investor & Analyst Day. September 25, 2018
Institutional Investor & Analyst Day September 25, 2018 Susan Morrison EVP & Chief Administrative Officer SLIDE 2 AGENDA Welcome. Company Vision. Technology Roadmap and Product Innovation. Financial Outlook
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationconfidently live life with ease Management Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause
More informationINVESTOR DAY JUN 5, 2018 NEW YORK CITY
INVESTOR DAY JUN 5, 2018 NEW YORK CITY HOOMAN HAKAMI EVP AND GROUP PRESIDENT DIABETES GROUP FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions
More informationCanaccord Growth Conference August confidently live life with ease
Canaccord Growth Conference August 2018 confidently live life with ease Forward-Looking Statements This presentation contains forward-looking statements that are not purely historical regarding Senseonics
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationInsulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education
Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history
More information10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:
DEXCOM G5 MOBILE CGM COMPATIBLE B 100% 235 u INSULIN ON BOARD: OPTIONS 10:20 AM March 5, 2017 400 350 300 250 200 150 100 50 1.1 u 1:09 hrs BOLUS 124 mg/dl 3 HRS The pump that gets updated, not outdated.
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationPredicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY
Predicts and helps prevent lows with * zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Basal-IQ Technology is not a substitute for active self-management of your diabetes. Please see back cover for
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationADA 2018 JUN 25, 2018 ORLANDO, FLORIDA
ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions and expectations that involve uncertainties
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationPeople with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT
Position Statement People with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT Diabetes Australia believes that people with diabetes should have choice and access
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationItamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationFirst Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International
First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International Tom Hein, CFO Safe Harbor Statement Except for historical information contained herein, the statements
More informationThe pump that gets updated, not outdated. *
FULLY FUNDED for eligible patients. The pump that gets updated, not outdated. * * Charges may apply. Dexcom CGM is not currently funded and is sold separately. Small pump. Big features. The simple-to-use
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationINSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.
INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. Waterproof to a depth
More informationJDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director
JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC
More informationValeritas. Corporate Presentation. NASDAQ: VLRX October Improving health and simplifying life for people with diabetes Valeritas, Inc.
Valeritas Corporate Presentation NASDAQ: VLRX October 2018 Improving health and simplifying life for people with diabetes Forward Looking Statements This presentation shall not be deemed an offer to sell
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationValeritas. Cowen Health Care Conference. Corporate Presentation. NASDAQ: VLRX March 12, 2018
Cowen Health Care Conference Valeritas Corporate Presentation NASDAQ: VLRX March 12, 2018 Improving health and simplifying life for people with diabetes NASDAQ: VLRX John Timberlake, CEO Improving health
More informationDexCom, Inc. FDA releases draft guidelines for artificial pancreas system precursor
DexCom, Inc. Company Description: DexCom is a real-time diagnostics medical device company focused on the continuous glucose monitoring (CGM) market for both diabetics and critical care patients. The company
More informationCorporate Presentation. First Quarter 2018
Corporate Presentation First Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationThe Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes
The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,
More informationApproved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.
Reference #: MC/L008 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationAbbott FreeStyle Libre Pro System
, the Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationBASICS OF INSULIN PUMPS. Jennifer Okemah MS RD BCADM CDE CSSD
BASICS OF INSULIN PUMPS Jennifer Okemah MS RD BCADM CDE CSSD SPEAKER DISCLOSURES: Contracted trainer for Animas, Omnipod, Medtronic Dexcom Advisory Board Sanofi Advisory Board Sanofi Contracted Speaker
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation November 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationCorporate Presentation. June 2017
v Corporate Presentation June 2017 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
More informationINSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.
INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. MORE TIME HERE TO USING
More informationInvestor Presentation May 2016
Investor Presentation May 2016 Forward Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forwardlooking statements as that term is defined
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationAbbott FreeStyle Libre Pro System
Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:
More informationDesigned with your patients lives in mind
The Accu-Chek Insight diabetes therapy system Designed with your patients lives in mind With pre-filled insulin cartridge Designed for easy patient training The Accu-Chek Insight diabetes therapy system
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationDIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson
DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More informationStraumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010
Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%
More informationNASDAQ: ELGX December Innovation that Empowers
NASDAQ: ELGX www.endologix.com December 2014 Innovation that Empowers Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationForward Looking Statements and Further Information
JANUARY 2015 [ 1 ] Forward Looking Statements and Further Information SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationCorporate Presentation. Second Quarter 2018
Corporate Presentation Second Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationNatus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017
Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationInvestor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications
Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available
More informationImportant Information about your 2.0 ml Animas Insulin Pump Cartridges
URGENT: INSULIN PUMP 2.0 ml CARTRIDGE RECALL February 24, 2011 Dear Animas Pumper: Important Information about your 2.0 ml Animas Insulin Pump Cartridges Animas Corporation is dedicated to supporting pumpers
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationEdwards Lifesciences. Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring
Edwards Lifesciences Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring Use of Non-GAAP Financial Measures Unless otherwise indicated, all figures are GAAP financial
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 02/13/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationOBJECTIVES THE PAST INNOVATIVE TECHNOLOGY & DIABETES DIABETES MIS MANAGEMENT IMPROVEMENTS IN DIABETES MANAGEMENT
OBJECTIVES INNOVATIVE TECHNOLOGY & DIABETES TRISHA PORRETTI, RN, BSN, CDE PWD FOR 25 YEARS Identify important safety features and differences of 3 Continuous Glucose Monitoring (CGM) systems Identify important
More informationCowen Healthcare Conference March 12, 2018
Cowen Healthcare Conference March 12, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationFuture Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump
Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes
Protocol Artificial Pancreas Device Systems Medical Benefit Effective Date: 07/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18, 05/18, 01/19 Preauthorization
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More information